M. Degardin

3.6k total citations · 1 hit paper
37 papers, 2.3k citations indexed

About

M. Degardin is a scholar working on Otorhinolaryngology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Degardin has authored 37 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Otorhinolaryngology, 21 papers in Oncology and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Degardin's work include Head and Neck Cancer Studies (22 papers), Lung Cancer Treatments and Mutations (11 papers) and Head and Neck Surgical Oncology (8 papers). M. Degardin is often cited by papers focused on Head and Neck Cancer Studies (22 papers), Lung Cancer Treatments and Mutations (11 papers) and Head and Neck Surgical Oncology (8 papers). M. Degardin collaborates with scholars based in France, Belgium and Spain. M. Degardin's co-authors include Éva Remenár, Jan B. Vermorken, Didier Cupissol, Thierry Gorlia, John S. Stewart, S. Jelić, Ricard Mesı́a, Jan Betka, Jacques Bernier and Jean-Louis Lefèbvre and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

M. Degardin

35 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer

2007 1.2k citations Jan B. Vermorken, Éva Remenár et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Degardin France	17	1.4k	1.2k	1.0k	838	311	37	2.3k
A. Trotti United States	7	1.4k 1.0×	709 0.6×	918 0.9×	637 0.8×	491 1.6×	15	2.2k
Rui Guo China	27	1.5k 1.1×	891 0.8×	904 0.9×	634 0.8×	198 0.6×	93	2.2k
C. Sire France	13	2.2k 1.6×	895 0.8×	1.5k 1.5×	1.0k 1.2×	185 0.6×	23	2.5k
E. Maillard France	14	1.8k 1.3×	1.1k 0.9×	1.8k 1.7×	1.7k 2.0×	331 1.1×	40	3.3k
Jean-Louis Lefèbvre France	5	2.9k 2.1×	1.4k 1.2×	2.1k 2.0×	1.2k 1.4×	419 1.3×	6	3.7k
B. Rhein France	11	1.9k 1.3×	741 0.6×	1.3k 1.3×	852 1.0×	141 0.5×	19	2.2k
A A Forastiere United States	9	1.5k 1.1×	911 0.8×	1.1k 1.1×	605 0.7×	232 0.7×	14	2.0k
Ding-Jen Lee United States	8	2.1k 1.5×	878 0.8×	1.5k 1.5×	1.1k 1.3×	277 0.9×	12	2.8k
Philippe Bergerot France	9	1.6k 1.1×	629 0.5×	1.2k 1.1×	872 1.0×	127 0.4×	13	2.0k
C. Fallai Italy	25	1.4k 1.0×	659 0.6×	1.0k 1.0×	943 1.1×	148 0.5×	93	2.3k

Countries citing papers authored by M. Degardin

Since Specialization

Citations

This map shows the geographic impact of M. Degardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Degardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Degardin more than expected).

Fields of papers citing papers by M. Degardin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Degardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Degardin. The network helps show where M. Degardin may publish in the future.

Co-authorship network of co-authors of M. Degardin

This figure shows the co-authorship network connecting the top 25 collaborators of M. Degardin. A scholar is included among the top collaborators of M. Degardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Degardin. M. Degardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fortpied, Catherine, George Koutsodontis, Margaritis Avgeris, et al.. (2017). Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study. Annals of Oncology. 28(9). 2213–2218. 11 indexed citations

Fayette, Jérôme, Laurence Digue, Céline Ferlay, et al.. (2016). PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy. Annals of Oncology. 27. vi331–vi331. 2 indexed citations

Guigay, J., Emmanuel Chamorey, F. Mornex, et al.. (2016). Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study). Annals of Oncology. 27. vi334–vi334. 3 indexed citations

Seiwert, Tanguy Y., Jérôme Fayette, Didier Cupissol, et al.. (2014). A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Annals of Oncology. 25(9). 1813–1820. 138 indexed citations

Lartigau, Éric, Emmanuelle Tresch, Juliette Thariat, et al.. (2013). Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer. Radiotherapy and Oncology. 109(2). 281–285. 133 indexed citations

Kramar, Andrew, S. Dewas, Bernard Coche‐Dequeant, et al.. (2012). Salvage Stereotactic Reirradiation With or Without Cetuximab for Locally Recurrent Head-and-Neck Cancer: A Feasibility Study. International Journal of Radiation Oncology*Biology*Physics. 84(1). 203–209. 81 indexed citations

Penel, Nicolas, Stéphanie Clisant, Éric Dansin, et al.. (2010). Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care. British Journal of Cancer. 102(8). 1207–1212. 22 indexed citations

Herpen, Carla M.L. van, Murielle Mauer, Ricard Mesı́a, et al.. (2010). Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323). British Journal of Cancer. 103(8). 1173–1181. 39 indexed citations

Lefèbvre, Jean Louis, et al.. (2004). Treatment of laryngeal cancer: the permanent challenge. Expert Review of Anticancer Therapy. 4(5). 913–920. 12 indexed citations

10.

Vermorken, Jan B., Éva Remenár, C. van Herpen, et al.. (2004). Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head andneck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Journal of Clinical Oncology. 22(14_suppl). 5508–5508. 75 indexed citations

11.

Duffaud, Florence, Markus Borner, P. Chollet, et al.. (2004). Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. European Journal of Cancer. 40(18). 2748–2752. 30 indexed citations

12.

Pivot, Xavier, Éric Raymond, Brigitte Laguerre, et al.. (2001). Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. British Journal of Cancer. 85(5). 649–655. 67 indexed citations

13.

Penel, Nicolas, et al.. (2001). Fièvre et tumeur solide : valeur diagnostique de la procalcitonine et de la protéine C réactive. La Revue de Médecine Interne. 22(8). 706–714. 12 indexed citations

14.

Penel, Nicolas, M. Degardin, Frédéric Frippiat, & É. Hachulla. (2000). Existe-t-il des critères diagnostiques en faveur d'une fièvre paranéoplasique ?. La Revue de Médecine Interne. 21(8). 684–692. 5 indexed citations

15.

Penel, Nicolas, Mai Nguyen, M. Degardin, & Charles Fournier. (2000). Evaluation de la fonction glomérulaire par le dosage de la cystatine C. Absence d'influence de l'état nutritionnel. Immuno-analyse & Biologie Spécialisée. 15(4). 255–257.

16.

Rizzoli, R., D. Thiébaud, Nigel Bundred, et al.. (1999). Serum Parathyroid Hormone-Related Protein Levels and Response to Bisphosphonate Treatment in Hypercalcemia of Malignancy. The Journal of Clinical Endocrinology & Metabolism. 84(10). 3545–3550. 32 indexed citations

17.

Degardin, M., et al.. (1997). Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN). European Journal of Cancer. 33. S187–S187. 1 indexed citations

18.

Pecherstorfer, Martin, Z. Herrmann, Jean‐Jacques Body, et al.. (1996). Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.. Journal of Clinical Oncology. 14(1). 268–276. 98 indexed citations

19.

Degardin, M., Jean Pierre Armand, Bernard Chevallier, et al.. (1995). A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Investigational New Drugs. 13(3). 253–255. 20 indexed citations

20.

Degardin, M., et al.. (1994). Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Annals of Oncology. 5(5). 423–426. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact